About Cardiome
Cardiome is a Healthcare company based in Vancouver (Canada) founded in 1990. Therapies for heart and circulatory disorders are developed and commercialized. Cardiome has completed 1 acquisition, including ADVANZ PHARMA. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Diversified.
Company details
Cardiome Pharma Corp. carries out product-focused and patient centric research for drug development dedicated to the development and commercialization of treatments for disorders of the heart and circulatory system. It has BrinavessTM (vernakalant IV) (in collaboration with Merck), which aids in the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, approved in Europe and Latin America and Phase 3 in other regions. It also has a candidate Vernakalant (oral) in Phase 2 in the pipeline.
- Headquarters Vancouver, Canada
- SectorsHealthcare
- Website cardiome.com
- Social LinkedIn
- Investments & Acquisitions
Investments & Acquisitions by Cardiome
Cardiome has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ADVANZ PHARMA.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
ADVANZ PHARMA is engaged in providing specialty and rare disease medicines. | correvio.com | Vancouver, Canada | 1986 | Nov 2013 | •••• |
Complete acquisition details for Cardiome
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Cardiome
2 dated milestones of Cardiome across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Cardiome is founded.
- Acquisition Acquires ADVANZ PHARMA.
Web traffic of Cardiome
Websites that share an audience with Cardiome (cardiome.com).
Websites whose visitors overlap most with Cardiome. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
phytopharm.com | phytopharm.com | 100% | – | ||
kinexpharma.com | kinexpharma.com | 100% | – | ||
| celladon.net | 100% | View details | |||
| collegiumpharma.com | 100% | 13.5K | #1,457,207 | View details | |
| prosidion.com | 100% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 21 similar websites and full traffic analytics for Cardiome
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 21 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cardiome
Complete news archive for Cardiome
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cardiome
Cardiome was founded in 1990.
Cardiome is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Cardiome Pharma Corp. carries out product-focused and patient centric research for drug development dedicated to the development and commercialization of treatments for disorders of the heart and circulatory system. It has BrinavessTM (vernakalant IV) (in collaboration with Merck), which aids in the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, approved in Europe and Latin America and Phase 3 in other regions. It also has a candidate Vernakalant (oral) in Phase 2 in the pipeline.
Cardiome has made 1 acquisition, including ADVANZ PHARMA.